Amundi’s Atara Biotherapeutics ATRA Stock Holding History

Amundi’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-294	Closed	-$20.4K	–	2034
2023 Q1	$20.4K	Hold	294	–	–	﹤0.01%	1960
2022 Q4	$26.9K	Hold	294	–	–	﹤0.01%	1769
2022 Q3	$30K	Buy	+294	New	+$33K	﹤0.01%	1725
2021 Q3	–	Sell	-477	Closed	-$185K	–	1566
2021 Q2	$185K	Buy	+477	New	+$170K	﹤0.01%	1392

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amundi's ATRA Position: Q2 2023 in Review

Amundi sold out of Atara Biotherapeutics (ATRA) in Q2 2023, closing a stake of 294 shares — an estimated $20.4K sold.

Amundi first reported a position in ATRA in Q2 2021 and held it in 4 quarters. The position peaked at $185K in Q2 2021. 118 funds tracked by Wall St. Rank hold ATRA as of Q2 2023.

Amundi reported no remaining Atara Biotherapeutics position as of Q2 2023 after selling out during the quarter.
Amundi sold 294 Atara Biotherapeutics shares in Q2 2023, an estimated $20.4K.
Amundi first reported a position in Atara Biotherapeutics in Q2 2021 and held it in 4 quarters.
Amundi's Atara Biotherapeutics position peaked at $185K in Q2 2021.
118 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2023.

Based on Amundi's 13F filing for Q2 2023, filed 14 Aug 2023.